Mountain Manor Treatment Center
Baltimore, Maryland, 21229, United States
NCT Number: NCT02063984
This study will continue research designed to improve treatment outcomes for adolescent substance use disorders by integrating neuroscience- and behaviorally-based treatments. In particular, this project will be the first to evaluate whether Working Memory Training can enhance cognitive function and reduce impulsive decision making to improve abstinence outcomes. In addition, an adaptive abstinence-based incentive program will be evaluated as a new method for intervening with those who do not respond to their first-line treatment.
Looking for future studies?
Notify Me12 year–26 year
All sexes
Interventional
Not applicable
Baltimore, Maryland, 21229, United States
The study will test two novel strategies to enhance outcomes. Working Memory Training (WMT), an efficacious method for strengthening specific cognitive processes, aims to improve factors (e.g., delay discounting / impulsive decision-making) that have shown a strong relation to substance use and treatment response. Second, more intensive and higher magnitude CM (ICM) will be used to motivate abstinence among teens who are not abstinent by Week 4. The investigators hypothesize that these strategies will improve outcomes by modifying a fundamental cognitive system involved in making choices to engage in risky behavior and by increasing motivation to abstain in early nonresponders. Aim 1 will pilot and refine the new procedures in a community clinic in preparation for the randomized trial. A sequential, multiple assignment randomized trial (SMART) will allow the study to determine the most effective first-line treatment and the most effective adaptive strategy (Aim 2). All teens will begin treatment with CM or CM/WMT. After 4 weeks, responders will continue in their first-line treatments, while nonresponders will be randomized to ICM or to continue with first-line treatment. Aim 3 will conduct mechanistic analyses to assess whether cognitive changes related to WMT engender increased abstinence, and whether specific tailoring variables moderate treatment effects. Aim 4 will gather formative data on implementation factors to inform future large-scale studies and dissemination efforts. Primary hypotheses are: (1) first-line treatment with WMT will improve abstinence outcomes and reduce relapse; (2) strategies with ICM for nonresponders will result in better outcomes than those without; (3) WMT will reduce delay discounting, which will predict outcome. The unique approach holds promise for reducing multiple types of risky behaviors by affecting basic mechanisms that determine impulsive decision-making.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Participants must be 12 to 26 years of age, must live at home with the parent who will participate, report using marijuana during the previous 30 days or provide a marijuana-positive urine test, meet criteria for cannabis abuse or dependence, and have a parent who can participate.
Exclusion criteria
DSM criteria for dependence (likely to be adjusted for DSM-5 Use Disorder) on alcohol or other drugs other than marijuana (use of or meeting criteria for abuse of other substances will not be an exclusion criterion), active psychosis, severe medical or psychiatric illness limiting participation, or pregnant or breast-feeding.
Multiple group sessions weekly, one individual counseling session weekly with teen to review and discuss contingency management abstinence-based incentives
25 computer-delivered sessions of neurocognitive training
Other names: Cogmed, Inc
Time frame: Intervention weeks 1 to 14
Number of participants with any cannabis abstinence during treatment
Time frame: 14 week treatment period
Weeks of continuous abstinence during treatment
Time frame: Intervention weeks 1 to 14
Number of participants with any days of cannabis use during treatment
Time frame: The intervention period between Week 1 and Week 14
Percent of Days Used During the Treatment Period
Time frame: Treatment period between week 1 and week 14
Number of participants who achieved at least one week of abstinence
Time frame: Treatment period between week 1 and week 14
Mean weeks of continuous cannabis abstinence among those who achieved at least one week of abstinence
Dartmouth-Hitchcock Medical Center
Other
Behavioral Treatment of Adolescent Marijuana Use
Acronym: SMART
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06439329
Chemically-Induced Disorders, Mental Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT01148381
Chemically-Induced Disorders, Healthy Volunteers
Baltimore, Maryland, United States
View Trial DetailsNCT04632238
Chemically-Induced Disorders, Mental Disorders
Blauvelt, New York, United States
View Trial DetailsNCT07001020
Behavior, Chemically-Induced Disorders
Springfield, Oregon, United States
View Trial Details